← Back to Search

Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease

N/A
Waitlist Available
Led By Sudipto Mukherjee, MD, PhD
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months from last participant accrued
Awards & highlights
No Placebo-Only Group

Summary

This trial will use WES to learn more about rare blood diseases and identify possible treatments.

Eligible Conditions
  • Erdheim-Chester disease
  • LCH
  • Castleman's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months from last participant accrued
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months from last participant accrued for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of genomic analyses yielding genetic aberrations
Secondary study objectives
Completion rates of genetic counseling for germline mutations
Proportion of genomic analyses yielding actionable genetic aberrations
Referral rates for genetic counseling for germline mutations

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Genomic analysisExperimental Treatment1 Intervention
When a participant's disorder was diagnosed, blood or tissue specimen was collected. A part of the tissue or blood will be sent to an outside company, Tempus, to be tested for specific genetic changes and the results will be sent back to participants' physician.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Genetic testing
2017
N/A
~5890

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor
469 Previous Clinical Trials
33,335 Total Patients Enrolled
Sudipto Mukherjee, MD, PhDPrincipal InvestigatorCleveland Clinic, Case Comprehensive Cancer Center
3 Previous Clinical Trials
53 Total Patients Enrolled
~30 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top